NEW TREATMENT FOR MULTIPLE SCLEROSIS TEVA
By Adnews Staff
Marion Partners Canada of Laval, Quebec introduced a new drug this week that the company says reduces the number of attacks on the nervous system from multiple sclerosis. Called Copaxone, the drug works by modifying the immune system in such a way as to decrease the body's attack on the myeline sheath. Without protection, the myelin sheath is damaged by MS, affecting nerve transmission to the brain. Medical journal advertising for Copaxone will begin by the end of the year. It will be created by SMW Advertising of Toronto.
« Back Next »
Comments
blog comments powered by Disqus